{"id":"https://openalex.org/W2000739170","doi":"https://doi.org/10.1002/ibd.21328","title":"Dosage adjustment during long-term adalimumab treatment for Crohn\u02bcs disease: Clinical efficacy and pharmacoeconomics","display_name":"Dosage adjustment during long-term adalimumab treatment for Crohn\u02bcs disease: Clinical efficacy and pharmacoeconomics","alternate_titles":[],"publication_year":2010,"publication_date":"2010-05-10","ids":{"openalex":"https://openalex.org/W2000739170","doi":"https://doi.org/10.1002/ibd.21328","mag":"2000739170","pmid":"https://pubmed.ncbi.nlm.nih.gov/20848500"},"language":"en","primary_location":{"id":"doi:10.1002/ibd.21328","doi":"https://doi.org/10.1002/ibd.21328","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ibd.21328","pdf_url":null,"source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000739170"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032150391","display_name":"William J. Sandborn","orcid":"https://orcid.org/0000-0002-3314-7960","observed_orcids":["https://orcid.org/0000-0002-3314-7960"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William J. Sandborn","raw_affiliation_strings":["Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. sandborn.william@mayo.edu","Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, Minnesota"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. sandborn.william@mayo.edu","institution_ids":["https://openalex.org/I1330342723"]},{"raw_affiliation_string":"Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, Minnesota","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108095099","display_name":"Jean\u2013Fr\u00e9d\u00e9ric Colombel","orcid":"https://orcid.org/0000-0001-6472-249X","observed_orcids":["https://orcid.org/0000-0001-6472-249X"]},"institutions":[{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]},{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jean-Fr\u00e9d\u00e9ric Colombel","raw_affiliation_strings":["Centre Hospitalier Universitaire de Lille, H\u00f4pital Claude Huriez, Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre Hospitalier Universitaire de Lille, H\u00f4pital Claude Huriez, Lille, France","institution_ids":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059435501","display_name":"Stefan Schreiber","orcid":"https://orcid.org/0000-0003-2254-7771","observed_orcids":["https://orcid.org/0000-0003-2254-7771"]},"institutions":[{"id":"https://openalex.org/I32021983","display_name":"Christian-Albrechts-Universit\u00e4t zu Kiel","ror":"https://ror.org/04v76ef78","country_code":"DE","type":"education","lineage":["https://openalex.org/I32021983"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stefan Schreiber","raw_affiliation_strings":["First Department of Medicine, Christian-Albrechts University, Kiel, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Medicine, Christian-Albrechts University, Kiel, Germany","institution_ids":["https://openalex.org/I32021983"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110881723","display_name":"Scott Eric Plevy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Scott E. Plevy","raw_affiliation_strings":["Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110012643","display_name":"Paul F. Pollack","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Paul F. Pollack","raw_affiliation_strings":["Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, Illinois","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038779972","display_name":"Anne Martin Robinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anne M. Robinson","raw_affiliation_strings":["Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, Illinois","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104088201","display_name":"Jingdong Chao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jingdong Chao","raw_affiliation_strings":["Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040838985","display_name":"Parvez M Mulani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Parvez Mulani","raw_affiliation_strings":["Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois","institution_ids":["https://openalex.org/I4210088555"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3862,"currency":"USD","value_usd":3862},"apc_paid":null,"fwci":6.5621,"has_fulltext":false,"cited_by_count":86,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.9650797,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"17","issue":"1","first_page":"141","last_page":"151"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/crohn-s-disease","display_name":"Crohn's disease","score":0.9879999756813049}],"concepts":[{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.9387831687927246},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9192144870758057},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6497694253921509},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6295724511146545},{"id":"https://openalex.org/C2779280984","wikidata":"https://www.wikidata.org/wiki/Q1472","display_name":"Crohn's disease","level":3,"score":0.5717114806175232},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4835036098957062},{"id":"https://openalex.org/C2776738588","wikidata":"https://www.wikidata.org/wiki/Q1567856","display_name":"Pharmacoeconomics","level":2,"score":0.48123717308044434},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.46764159202575684},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2740262746810913},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.14593932032585144}],"mesh":[{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D003424","descriptor_name":"Crohn Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003424","descriptor_name":"Crohn Disease","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008134","descriptor_name":"Long-Term Care","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017850","descriptor_name":"Economics, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/ibd.21328","doi":"https://doi.org/10.1002/ibd.21328","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ibd.21328","pdf_url":null,"source":{"id":"https://openalex.org/S45123234","display_name":"Inflammatory Bowel Diseases","issn_l":"1078-0998","issn":["1078-0998","1536-4844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory Bowel Diseases","raw_type":"journal-article"},{"id":"pmid:20848500","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20848500","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Inflammatory bowel diseases","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1585045402","https://openalex.org/W1607808246","https://openalex.org/W1964015549","https://openalex.org/W1978680434","https://openalex.org/W1979948289","https://openalex.org/W1991810959","https://openalex.org/W1994020662","https://openalex.org/W2022507641","https://openalex.org/W2048112403","https://openalex.org/W2075379005","https://openalex.org/W2090685459","https://openalex.org/W2095164057","https://openalex.org/W2097155282","https://openalex.org/W2118422544","https://openalex.org/W2121609590","https://openalex.org/W2137775651","https://openalex.org/W2152026434","https://openalex.org/W2166360124","https://openalex.org/W2168370388","https://openalex.org/W2171341132","https://openalex.org/W2321453230","https://openalex.org/W3149527659","https://openalex.org/W4230184840"],"related_works":["https://openalex.org/W4252272740","https://openalex.org/W2978299048","https://openalex.org/W2979206558","https://openalex.org/W2774953515","https://openalex.org/W1996535816","https://openalex.org/W2312320647","https://openalex.org/W2067270411","https://openalex.org/W2045351208","https://openalex.org/W3031289501","https://openalex.org/W1994020662"],"abstract_inverted_index":{"BACKGROUND:":[0],"Data":[1],"from":[2],"CHARM,":[3],"a":[4,183,200,251],"56-week,":[5],"randomized":[6,32,88,216],"controlled":[7],"trial":[8,126],"of":[9,26,47,58,196,238],"adalimumab":[10,27,35,76,82,90],"for":[11,234],"patients":[12,53,63,87,106,132,164,215],"with":[13,54,246],"moderately":[14],"to":[15,23,33,73,80,89,102,119,191,217,223,230],"severely":[16],"active":[17],"Crohn's":[18],"disease":[19],"(CD),":[20],"were":[21,44],"used":[22],"evaluate":[24],"outcomes":[25],"dosage":[28],"adjustment.":[29],"METHODS:":[30],"Patients":[31],"blinded":[34,95,218],"40":[36],"mg":[37],"every":[38],"other":[39],"week":[40],"(EOW)":[41],"in":[42],"CHARM":[43],"the":[45,48,125,162],"focus":[46],"analysis.":[49],"At":[50],"\u226512":[51],"weeks,":[52],"flares":[55,235],"or":[56,236],"lack":[57,237],"response":[59,239],"versus":[60,240],"baseline":[61,187],"(including":[62],"who":[64,165],"responded":[65],"and":[66,78,98,115,153,178,227,250],"then":[67,79],"lost":[68],"response)":[69],"could":[70],"move":[71],"sequentially":[72],"open-label":[74],"(OL)":[75],"EOW":[77,96,113,169,209,219,225],"OL":[81,103,108,168,224,231],"weekly.":[83],"RESULTS:":[84],"Of":[85,105,130,161,214],"260":[86],"EOW,":[91],"140":[92],"(54%)":[93],"continued":[94,112],"therapy":[97,114,226,233,243],"120":[99],"(46%)":[100],"moved":[101,118,222,229],"therapy.":[104,129,193],"on":[107,127,133,167],"therapy,":[109,135,170,220],"49":[110,163],"(19%)":[111],"71":[116,131],"(27%)":[117],"weekly":[120,128,134,192,232],"therapy;":[121],"36":[122],"(14%)":[123],"completed":[124],"37%":[136],"achieved":[137,147,155,172,176,180],"clinical":[138,173,248],"remission":[139],"(Crohn's":[140],"Disease":[141],"Activity":[142],"Index":[143],"[CDAI]":[144],"<150),":[145],"58%":[146],"CR-100":[148],"(CDAI":[149,157],"decreased":[150,158],"\u2265100":[151],"points),":[152],"63%":[154,179],"CR-70":[156],"\u226570":[159],"points).":[160],"remained":[166],"39%":[171],"remission,":[174],"59%":[175],"CR-100,":[177],"CR-70.":[181],"In":[182],"logistic":[184],"regression,":[185],"greater":[186],"CDAI":[188],"predicted":[189],"changing":[190],"A":[194],"model":[195],"dosage-adjustment":[197],"cost":[198,204,211,253],"indicated":[199],"modest":[201],"per-patient":[202],"drug-acquisition":[203],"increase":[205],"($574":[206],"over":[207],"yearly":[208],"dosing":[210],"[$22,518]).":[212],"CONCLUSIONS:":[213],"19%":[221],"27%":[228],"baseline.":[241],"Weekly":[242],"was":[244],"associated":[245],"clear":[247],"benefits":[249],"small":[252],"increase.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2000739170","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-22T12:46:00.618207","created_date":"2016-06-24T00:00:00"}
